Du har inte javascript påslaget. Det innebär att många funktioner inte fungerar. För mer information om Vinnova, ta kontakt med oss.

Förarbete inför klinisk multicenter studie

Diarienummer
Koordinator UTIlizer AB
Bidrag från Vinnova 292 350 kronor
Projektets löptid augusti 2022 - augusti 2023
Status Avslutat
Utlysning Förberedelseprojekt inför internationell ansökan inom precisionshälsa
Ansökningsomgång Förberedelseprojekt inför internationell ansökan inom hälsa och mat

Viktiga resultat som projektet gav

We conducted a pilot study with a urology clinic where prototype adaption based on feedback and requirements were carried out. Additionally, an international consortium including Karolinska Institutet, Region Kronoberg, Umeå University, CHROMagar (France), University of Oxford (UK), and University of Rennes (France) was formed to seek EU funding for the development of a multicenter clinical trial. Finally, the consortium established a study protocol for comparative multicenter clinical studies to collect data for our CE IVDR application.

Långsiktiga effekter som förväntas

We have gained valuable experience in conducting a study in primary care/point-of-care settings and have assembled a robust consortium with an impressive range of competences. This accumulated experience and our consortium have empowered us to develop a strong study protocol and compose a compelling application for Eureka/Eurostars funding in early 2024. Additionally, we have opted to incorporate an additional work package into our draft for the development and testing of added functionality of antibiotic susceptibility testing.

Upplägg och genomförande

The iterative process of the pilot study where insights led to prototype adoptions and understanding our intended users requirements has positioned us well to deliver an effective and user-friendly solution. We are extremely pleased with the consortium we have assembled across Sweden, the UK, and France to seek EU funding, and to conduct multicenter clinical trials. With this network of well-respected universities, we will be able to conduct high-quality, objective clinical trials and kickstart our marketing efforts in our primary target markets.

Texten på den här sidan har projektgruppen själv formulerat. Innehållet är inte granskat av våra redaktörer.

Senast uppdaterad 29 september 2023

Diarienummer 2022-01431